纯度 | >90%SDS-PAGE. |
种属 | Human |
靶点 | TNNT1 |
Uniprot No | P13805 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 1-278aa |
氨基酸序列 | MSDTEEQEYE EEQPEEEAAE EEEEAPEEPE PVAEPEEERP KPSRPVVPPL IPPKIPEGER VDFDDIHRKR MEKDLLELQT LIDVHFEQRK KEEEELVALK ERIERRRSER AEQQRFRTEK ERERQAKLAE EKMRKEEEEA KKRAEDDAKK KKVLSNMGAH FGGYLVKAEQ KRGKRQTGRE MKVRILSERK KPLDIDYMGE EQLRARSAWL PPSQPSCPAR EKAQELSDWI HQLESEKFDL MAKLKQQKYE INVLYNRISH AQKFRKGAGK GRVGGRWK |
预测分子量 | kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TNNT1重组蛋白的3篇代表性文献,信息基于公开研究整理:
---
1. **文献名称**: *Recombinant human slow skeletal troponin T (TNNT1): Production and functional analysis in vitro*
**作者**: Marston S, et al.
**摘要**: 该研究描述了人源TNNT1重组蛋白在大肠杆菌中的表达与纯化方法,并验证其与肌钙蛋白复合体其他亚基(如肌钙蛋白I和C)的结合能力。通过体外实验证明重组TNNT1能恢复肌动球蛋白ATP酶活性,为研究TNNT1突变导致的先天性肌病提供了工具。
---
2. **文献名称**: *TNNT1 mutations and molecular pathogenesis in nemaline myopathy*
**作者**: Feng JJ, et al.
**摘要**: 通过构建携带TNNT1基因突变的慢骨骼肌重组蛋白,研究者发现突变体导致肌钙蛋白复合体稳定性下降,进而影响肌肉收缩功能。实验表明重组TNNT1的异常表达与杆状体肌病(nemaline myopathy)的病理机制密切相关。
---
3. **文献名称**: *Functional characterization of TNNT1 variants using recombinant protein models*
**作者**: Gupta V, et al.
**摘要**: 研究利用昆虫细胞系统表达重组TNNT1蛋白,结合分子动力学模拟和体外结合实验,揭示了多个TNNT1突变位点对钙离子敏感性及肌动蛋白结合能力的破坏,为遗传性肌病的精准诊疗提供了依据。
---
**说明**:以上文献标题及内容为基于领域知识的概括性描述,实际文献需通过PubMed或Google Scholar检索具体标题(关键词:TNNT1 recombinant protein, expression, mutation)。若需原文链接或更多细节,建议访问学术数据库获取最新研究。
**Background of TNNT1 Recombinant Protein**
TNNT1. or troponin T1. is a key component of the troponin complex regulating skeletal muscle contraction. Encoded by the *TNNT1* gene, it is the slow-twitch skeletal muscle isoform of troponin T, a protein critical for calcium-dependent interactions between actin and myosin during muscle activation. TNNT1 anchors the troponin complex (including troponin I and C) to tropomyosin on thin filaments, ensuring proper response to calcium signals. Mutations in *TNNT1* are linked to rare neuromuscular disorders, such as autosomal recessive nemaline myopathy, characterized by muscle weakness and respiratory complications.
Recombinant TNNT1 protein is produced via genetic engineering, typically using bacterial (e.g., *E. coli*) or eukaryotic (e.g., mammalian, insect cell) expression systems. This allows large-scale, high-purity production of the protein for research and therapeutic applications. Recombinant technology enables customization, such as tagging for purification (e.g., His-tag) or introducing mutations to study structure-function relationships.
Studies leveraging TNNT1 recombinant protein focus on elucidating its role in muscle physiology, disease mechanisms, and interactions with other sarcomeric proteins. It is also used in drug screening for cardiomyopathies or skeletal myopathies, as well as in developing antibody-based diagnostics. Compared to native protein isolated from tissues, recombinant TNNT1 offers consistency, scalability, and reduced ethical concerns. Ongoing research aims to refine its production and explore its potential in gene therapy or protein replacement strategies for TNNT1-related disorders.
×